<DOC>
	<DOCNO>NCT00416767</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil , leucovorin , irinotecan , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase II trial study well combination chemotherapy work first-line therapy treat patient locally advance metastatic neuroendocrine tumor duodenum pancreas remove surgery .</brief_summary>
	<brief_title>Combination Chemotherapy First-Line Therapy Treating Patients With Locally Advanced Metastatic Neuroendocrine Tumors Duodenum Pancreas That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine 6-month progression-free survival rate patient unresectable locally advanced metastatic neuroendocrine tumor duodenum/pancreas treat fluorouracil , leucovorin calcium , irinotecan hydrochloride first-line chemotherapy . Secondary - Determine tumor biologic response 6 , 12 , 18 , 24 month patient treat regimen . - Determine duration response primary tumor patient treat regimen . - Determine tolerability regimen patient . - Determine progression-free survival patient treat regimen . - Determine overall survival patient treat regimen . OUTLINE : This multicenter study . Patients receive irinotecan hydrochloride IV 90 minute leucovorin calcium IV 2 hour day 1 fluorouracil IV 46 hour day 1 2 . Courses repeat every 14 day absence disease progression unacceptable toxicity . After completion study therapy , patient follow every 3 month 1 year every 6 month thereafter . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neuroendocrine tumor duodenum/pancreas histology bone scan Functional nonfunctional tumor Tumor meet ≥ 1 follow criterion : Hepatic extrahepatic metastasis Progressive locally advance tumor ( primary adenopathy ) Unresectable disease Tumor differentiate meet follow criterion : Ki 67 ≤ 15 % Less 10 mitoses per 10 large field Measurable evaluable disease Target lesion must meet 1 follow criterion within past 6 month : Increase 20 % long diameter New metastasis detect Minimum size lesion must 1 follow : More 15 mm metastasis More 50 mm primary tumor local lymph node PATIENT CHARACTERISTICS : WHO performance status 02 Creatinine ≤ 1.5 mg/dL Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.8 mg/dL No coronary insufficiency symptomatic cardiac disease No intestinal obstruction , enteropathy , uncontrolled chronic diarrhea No Gilbert 's disease No psychological , social , familial , geographic condition would preclude study treatment Not pregnant nursing Fertile patient must use effective contraception 6 month completion study therapy No condition would preclude study therapy PRIOR CONCURRENT THERAPY : No prior adjuvant radiotherapy At least 3 month since prior interferon Prior somatostatin analog antisecretories allow No prior treatment cancer No concurrent radiotherapy target lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>regional gastrointestinal carcinoid tumor</keyword>
	<keyword>gastrinoma</keyword>
	<keyword>insulinoma</keyword>
	<keyword>WDHA syndrome</keyword>
	<keyword>glucagonoma</keyword>
	<keyword>pancreatic polypeptide tumor</keyword>
	<keyword>somatostatinoma</keyword>
	<keyword>recurrent islet cell carcinoma</keyword>
</DOC>